Bio + Healthcare

Portfolio spotlight

Our Portfolio
benchling
benchling

Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.

Milestones
  • 2012 Founded
  • 2019 Partnered, Series C
benchling_graphic
delfi
delfi

Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.

Milestones
  • 2019 Founded
  • 2019 Partnered, Seed
Partner
delfi_graphic
encoded_therapeutics-rectangle
encoded_therapeutics-rectangle

Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.

Milestones
  • 2014 Founded
  • 2019 Partnered, Series C
Partner
encoded_therapeutics_graphic
gilead NASDAQ: GILD
gilead

Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.

Milestones
  • 1987 Founded
  • 1987 Incubated by Menlo Ventures
  • 1992 IPO; NASDAQ: GILD
gilead_graphic

H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
pillpackAcquired by Amazon
pillpack

PillPack is a full-service pharmacy that delivers a better, simpler experience through convenient packaging, modern technology, and personalized service.

Milestones
  • 2013 Founded
  • 2015 Partnered, Series C
  • 2018 Acquired by Amazon
pillpack_graphic
NASDAQ: PLRX

Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Milestones
  • 2015 Founded
  • 2018 Partnered, Series B
  • 2020 IPO; NASDAQ: PLRX
Partner
pliant_therapeutics_graphic
recursion NASDAQ: RXRX
recursion

Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.

Milestones
  • 2013 Founded
  • 2017 Partnered, Series B
  • 2021 IPO; NASDAQ: RXRX
recursion_graphic

Our perspective

Clear all
List view Grid view
Filters

Video: Engineering New Drugs With Generative AI at Genesis Therapeutics

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

Video: Early Cancer Detection With Delfi
Video: Reengineering Drug Discovery With Recursion

Partnership
is our
purpose.

Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna
Ophelia founder Zack Gray
Video: Fighting the Opioid Epidemic With Ophelia
mental health care graphic
Carefully Crafted Digital Approaches Can Improve Youths’ Mental Health Care

Announcing the Digital Health Founder’s Fellowship

Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship

Riva Health founders Dag Kittlaus and Tuhin Sinha

Video: Improving Heart Health With Riva

Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.

Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences
Don’t Forget the Pipes! Why Insurtech Infrastructure Is Poised to Be Huge!
Ophelia Health: Fighting the Opioid Epidemic by Making the Best Care Accessible
It’s Time to Crack the Complex Code of Benefits Tech

Life Science Is Being Transformed by Vertical SaaS

We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.

Join a
Menlo-backed
company.

The 5 Ps of Therapeutics Investing at Menlo
Video: Engineering New Drugs With Generative AI at Genesis Therapeutics

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

May 2, 2023Greg Yap
Video: Early Cancer Detection With Delfi

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

March 9, 2023Greg Yap
Video: Reengineering Drug Discovery With Recursion

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

March 9, 2023Greg Yap, Johnny Hu and Ph.D.
Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna

Cancer remains one of the leading causes of death in the U.S. and worldwide.

January 11, 2023Johnny Hu and Ph.D.
Video: Fighting the Opioid Epidemic With Ophelia

Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.

December 8, 2022Greg Yap
Carefully Crafted Digital Approaches Can Improve Youths’ Mental Health Care

In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.

December 7, 2022Greg Yap and Derek Xiao
Announcing the Digital Health Founder’s Fellowship

Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship

December 6, 2022Greg Yap
Video: Improving Heart Health With Riva

Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.

November 22, 2022Greg Yap
Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences

Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.

May 25, 2021JP Sanday
Don’t Forget the Pipes! Why Insurtech Infrastructure Is Poised to Be Huge!

Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.

April 27, 2021Steve Sloane
Ophelia Health: Fighting the Opioid Epidemic by Making the Best Care Accessible

Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.

April 22, 2021Greg Yap and Croom Beatty
It’s Time to Crack the Complex Code of Benefits Tech

The COVID-19 pandemic changed the world of benefits forever. Companies rethought the traditional office paradigm and re-evaluated the suite of benefits that provide a strong work experience for employees.

April 21, 2021Steve Sloane
Life Science Is Being Transformed by Vertical SaaS

We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.

April 14, 2021Matt Murphy, JP Sanday and Greg Yap
The 5 Ps of Therapeutics Investing at Menlo

At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.

March 31, 2021Greg Yap
loader.svg